Literature DB >> 20646658

[Efficiency of laparoscopic D2 radical gastrectomy in gastric cancer: experiences of 218 patients].

Jia-bin Wang1, Chang-ming Huang, Chao-hui Zheng, Ping Li, Jian-wei Xie, Bi-juan Lin, Hui-shan Lu.   

Abstract

OBJECTIVE: To explore the feasibility and efficacy of laparoscopic D2 radical gastrectomy in patients with gastric cancer.
METHODS: The clinical data of 529 patients with gastric cancer underwent D2 radical resection from January 2007 to March 2009 were analyzed retrospectively. Among the patients, 218 cases underwent laparoscopic D2 gastrectomy (LAG group) and 311 cases received open gastrectomy (OG group). The patients' operation, number of retrieved lymph nodes, recovery, postoperative morbidity and mortality were compared between the two groups.
RESULTS: The operative time in LAG group was (237 +/- 42) min, and was significantly longer than that in OG group [(229 +/- 42) min, P < 0.05]. However, the mean blood loss [(81 +/- 100) ml vs. (171 +/- 211) ml], number of patients needed blood transfusion (7 vs. 44 cases), first flatus time [(4.1 +/- 2.3) d vs. (5.0 +/- 1.4) d], time to resume soft diet [(4.5 +/- 2.2) d vs. (5.5 +/- 1.4) d] and postoperative hospital stay [(12 +/- 4) d vs. (14 +/- 4) d] in the two groups were all different statistically (P < 0.05), and all were better in LAG group. In LAG group, the operative time of patients with total gastrectomy was (250 +/- 46) min, and was significantly longer than that with distal gastrectomy (228 +/- 37) min (P < 0.05), but there was no significant differences in other aspects of patients' recovery between the two operation types. The postoperative morbidity of LAG group and OG group were 11.9% and 19.0%, respectively (P < 0.05). For all patients, the mean number of retrieved lymph nodes was (29 +/- 10) and the median number was 28. The mean number of retrieved lymph nodes was not significantly different between the two groups [(28 +/- 10) in LAG group vs. (29 +/- 9) in OG group, P > 0.05]. Thirteen patients (6.0%) converted to open surgery in LAG group.
CONCLUSION: Laparoscopic D2 radical gastrectomy is a safe and feasible procedure with quick recovery, and it is comparable with open gastrectomy in lymph node dissection.

Entities:  

Mesh:

Year:  2010        PMID: 20646658

Source DB:  PubMed          Journal:  Zhonghua Wai Ke Za Zhi        ISSN: 0529-5815


  5 in total

1.  Evaluation of laparoscopic total gastrectomy for advanced gastric cancer: results of a comparison with laparoscopic distal gastrectomy.

Authors:  Jian-Xian Lin; Chang-Ming Huang; Chao-Hui Zheng; Ping Li; Jian-Wei Xie; Jia-Bin Wang; Lu Jun; Qi-Yue Chen; Mi Lin; Ruhong Tu
Journal:  Surg Endosc       Date:  2015-07-25       Impact factor: 4.584

2.  Comparision of modified and conventional delta-shaped gastroduodenostomy in totally laparoscopic surgery.

Authors:  Chang-Ming Huang; Mi Lin; Jian-Xian Lin; Chao-Hui Zheng; Ping Li; Jian-Wei Xie; Jia-Bin Wang; Jun Lu
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

3.  Laparoscopy-assisted versus open gastrectomy with D2 lymph node dissection for advanced gastric cancer: a meta-analysis.

Authors:  Yu-Ling Huang; Hai-Guan Lin; Jian-Wu Yang; Fu-Quan Jiang; Tao Zhang; He-Ming Yang; Cheng-Lin Li; Yan Cui
Journal:  Int J Clin Exp Med       Date:  2014-06-15

4.  Which method is more suitable for advanced gastric cancer with enlarged lymph nodes, laparoscopic radical gastrectomy or open gastrectomy?

Authors:  Qi-Yue Chen; Chao-Hui Zheng; Ping Li; Jian-Wei Xie; Jia-Bin Wang; Jian-Xian Lin; Jun Lu; Long-Long Cao; Mi Lin; Ru-Hong Tu; Ze-Ning Huang; Ju-Li Lin; Chang-Ming Huang
Journal:  Gastric Cancer       Date:  2018-01-30       Impact factor: 7.370

5.  Surgical outcomes of 2041 consecutive laparoscopic gastrectomy procedures for gastric cancer: a large-scale case control study.

Authors:  Jian-Xian Lin; Chang-Ming Huang; Chao-Hui Zheng; Ping Li; Jian-Wei Xie; Jia-Bin Wang; Jun Lu; Qi-Yue Chen; Long-Long Cao; Mi Lin
Journal:  PLoS One       Date:  2015-02-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.